• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 23, 2015

View Archived Issues

In the clinic

Amicus Therapeutics Inc., of Cranbury, N.J., said its investigational new drug application, submitted to the FDA, is now effective, which allows the firm to begin site initiation and enrollment of a phase I/II study of ATB200 in patients with Pompe disease. Read More

Stock movers

Read More

Other news to note

Huya Bioscience International LLC, of San Diego, said the Japanese Ministry of Health, Labour and Welfare designated HBI-8000 an orphan drug in Japan for peripheral T-cell lymphoma. HBI-8000, a class I-selective oral histone deacetylase inhibitor, is completing a phase I open-label, dose-escalation trial in Japan, evaluating the drug's safety and pharmacokinetics in Japanese patients with non-Hodgkin lymphoma. Read More

Financings

Sunesis Pharmaceuticals Inc., of South San Francisco, said it closed underwritten offerings of 10.99 million shares of its common stock, which included the exercise of the underwriter's overallotment option of 1.43 million shares, at 84 cents per share, and 20,200 shares of its nonvoting series B convertible preferred stock at $840 each. The company received combined gross proceeds of about $26.2 million from those offerings. Read More

Adaptive licensing in Asia a good focus for revival as approvals lag

SINGAPORE – Getting East to meet West in drug approval guidelines might make more headway if regulators in Asia looked harder for adaptive licensing prospects, an idea that caught the attention of policymakers in Singapore in 2010, but has since fallen to the wayside regionally. Read More

Pre-IPO Hutchison kicks off China phase III trial for NETs drug sulfatinib

SHANGHAI – Hutchison Medipharma Ltd., of Shanghai, one of China's biotech pioneers with a deep pipeline of small-molecule oncology and autoimmune candidates, has started dosing Chinese patients with neuroendocrine tumors (NETs) in a phase III trial of sulfatinib. Read More

Vaccination nanoparticle could be treatment for metastatic cancer

Local vaccination with a nanoparticle generated a systemic immune response to tumors that subsequently fought metastases elsewhere in the body, researchers reported in the Dec. 21, 2015, online issue of Nature Nanotechnology. Read More

Time for new report card on FDA's response to drug globalization

Concerned about the FDA's ability to keep up with the oversight demands of the global drug supply chain, the House Energy and Commerce Committee wants an updated government report card on how the agency is doing, especially in China and India. Read More

Psivida skyrockets on 'extraordinary' phase III Medidur uveitis data

Shares of Psivida Corp., of Watertown, Mass., (NASDAQ:PSDV) shot up to a five-year high on above-average trading volume Tuesday after the company reported positive top-line results from its first phase III trial evaluating Medidur to treat chronic noninfectious uveitis affecting the posterior of the eye (posterior uveitis). Read More

Translation regulation: $40M series B shifts Effector into clinic mode

Two years after entering a crowded field seeking to control gene expression in treating cancer, Effector Therapeutics Inc. showed that its approach – the development of small-molecule translation regulators – has staying power by landing a $40 million series B to advance its first two programs into the clinic. Read More

FDA approves Actelion's drug to 'PAH'mp the brakes on lung disease progress

Christmas came early for Actelion Ltd., as the FDA approved its pulmonary arterial hypertension (PAH) treatment Uptravi (selexipag), putting the company on track to launch the oral prostacyclin receptor agonist early next month for use in delaying PAH progression and patients' risk of hospitalization for symptoms related to the condition. The therapy will be marketed by San Francisco-based Actelion Pharmaceuticals US Inc. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe